Effects of autocrine vascular endothelial growth factor (VEGF) in non-small cell lung cancer cell line A549

Molecular Biology Reports

Volumn 40, Issue 4, 2013, Pages 3093-3099

  Wang, Ying ^a   Huang, Lu ^a   Yang, Yunmei ^a   Xu, Liqian ^a   Yang, Ji ^a   Wu, Yue ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

ASODN; Autocrine; Endogenous; NSCLC; VEGF

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE; VASCULOTROPIN;

ARTICLE; AUTOCRINE EFFECT; CANCER CELL; CELL CYCLE G2 PHASE; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

APOPTOSIS; AUTOCRINE COMMUNICATION; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84878393102     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-012-2383-4     Document Type: Article

References (37)

1. Thompson E (2005) Latest advances and research in lung cancer. Drug News Perspect 18(6):405-411
2. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24(28):4539-4544. doi: 10.1200/jco.2005.04.4859
3. de Perrot M, Licker M, Robert J, Spiliopoulos A (1999) Time trend in the surgical management of patients with lung carcinoma. Eur J Cardiothorac Surg 15(4):433-437
4. Brescia FJ, Fontenot MRG, Johnson DH (1997) Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 15 (8):2996-3018
5. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT (2004) American society of clinical oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 22(2):330-353. doi: 10.1200/jco.2004.09.053
6. Han K, Cao W, Che J, Bo S, Guo X, Huang G, Ma L, Sun L, Gao C, Zhong B, Cao Z, Tucker SJ, Wang D (2009) First line chemotherapy with weekly docetaxel and cisplatin in elderly patients with advanced non-small cell lung cancer: a multicenter phase II study. J Thorac Oncol 4(4):512-517
7. Juergens R, Brahmer J, Ettinger D (2007) Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter. Cancer Chemother Pharmacol 59(5):621-629. doi: 10.1007/s00280-006-0304-8
8. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. New Eng J Med 346(2):92-98. doi: 10.1056/NEJMoa011954
9. Delbaldo C, Michiels S, Syz N, Soria J-C, Le Chevalier T, Pignon J-P (2004) Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer. J Am Med Assoc 292(4):470-484. doi: 10.1001/jama.292.4.470
10. Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219(4587):983-985
11. Byrne AM, Bouchier-Hayes DJ, Harmey JH (2005) Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 9(4):777-794. doi: 10.1111/j.1582-4934.2005.tb00379.x
12. Regina S, Rollin J, Blechet C, Iochmann S, Reverdiau P, Gruel Y (2008) Tissue factor expression in non-small cell lung cancer: relationship with vascular endothelial growth factor expression, microvascular density, and K-ras mutation. J Thorac Oncol 3(7):689-697. doi: 10.1097/JTO.0b013e31817c1b21
13. Du C, Fang M, Li Y, Li L, Wang X (2000) Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP Inhibition. Cell 102(1):33-42. doi: 10.1016/s0092-8674(00)00008-8
14. Ferrara N (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25(4):581-611. doi: 10.1210/er.2003-0027
15. Fontanini G, Vignati S, Boldrini L, Chinè S, Silvestri V, Lucchi M, Mussi A, Angeletti CA, Bevilacqua G (1997) Vascular endothelial growth factor is associated with neovascularization and influences progression of non-small cell lung carcinoma. Clin Cancer Res 3(6):861-865
16. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. New Eng J Med 350(23):2335-2342. doi: 10.1056/NEJMoa032691
17. Santos SCR, Dias S (2004) Internal and external autocrine VEGF/KDR loops regulate survival of subsets of acute leukemia through distinct signaling pathways. Blood 103(10):3883-3889. doi: 10.1182/blood-2003-05-1634
18. Zamecnik PC, Stephenson ML (1978) Inhibition of Rous sarcoma virus replication and cell transformation by a specific oligodeoxynucleotide. Proc Natl Acad Sci USA 75(1):280-284
19. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. CA Cancer J Clin 61(2):69-90. doi: 10.3322/caac.20107
20. Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer I 82(1):4-7. doi: 10.1093/jnci/82.1.4
21. Folkman J (1971) Tumor angiogenesis: therapeutic implications. New Eng J Med 285(21):1182-1186. doi: 10.1056/NEJM197111182852108
22. Folkman J (1990) Endothelial cells and angiogenic growth factors in cancer growth and metastasis. Introduction. Cancer Metastasis Rev 9(3):171-174
23. Takeda A, Stoeltzing O, Ahmad SA, Reinmuth N, Liu W, Parikh A, Fan F, Akagi M, Ellis LM (2002) Role of angiogenesis in the development and growth of liver metastasis. Ann Surg Oncol 9(7):610-616
24. Hicklin DJ, Ellis LM (2005) Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 23(5):1011-1027. doi: 10.1200/jco.2005.06.081
25. Kotteas EA, Charpidou AG, Syrigos KN (2010) Targeted therapy for non-small cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multi-kinase inhibitors. Anti-Cancer Drugs 21(2):151-168. doi: 110.1097/CAD.1090b1013e328334da328302
26. Pal SK, Figlin RA, Reckamp K (2010) Targeted therapies for non-small cell lung cancer: an evolving landscape. Mol Cancer Ther 9(7):1931-1944. doi: 10.1158/1535-7163.mct-10-0239
27. Feng Y, Hu J, Ma J, Feng K, Zhang X, Yang S, Wang W, Zhang J, Zhang Y (2011) RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Eur J Cancer 47(15):2353-2363
28. Yang Y, Bai Y, Xie G, Zhang N, Ma YP, Chen LJ, Jiang Y, Zhao X, Wei YQ, Deng HX (2010) Efficient inhibition of non-small-cell lung cancer xenograft by systemic delivery of plasmid-encoding short-hairpin RNA targeting VEGF. Cancer Biother Radiopharm 25(1):65-73
29. Galderisi U, Cascino A, Giordano A (1999) Antisense oligonucleotides as therapeutic agents. J Cell Physiol 181(2):251-257. doi: 10.1002/(sici)1097- 4652(199911)181:2<251:aid-jcp7>3.0.co;2-d
30. Acosta R, Montañez C, Gómez P, Cisneros B (2002) Delivery of antisense oligonucleotides to PC12 cells. Neurosci Res 43(1):81-86. doi: 10.1016/s0168-0102(02)00014-7
31. Bochot A, Couvreur P, Fattal E (2000) Intravitreal administration of antisense oligonucleotides: potential of liposomal delivery. Prog Retin Eye Res 19(2):131-147. doi: 10.1016/s1350-9462(99)00014-2
32. Lebedeva I, Benimetskaya L, Stein CA, Vilenchik M (2000) Cellular delivery of antisense oligonucleotides. Eur J Pharm Biopharm 50(1):101-119
33. Van Meir EG, Polverini PJ, Chazin VR, Su Huang HJ, de Tribolet N, Cavenee WK (1994) Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat Genet 8(2):171-176. doi: 10.1038/ng1094-171
34. Gerber H-P, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC, Ferrara N (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417(6892):954-958
35. Katoh O, Takahashi T, Oguri T, Kuramoto K, Mihara K, Kobayashi M, Hirata S, Watanabe H (1998) Vascular endothelial growth factor inhibits apoptotic death in hematopoietic cells after exposure to chemotherapeutic drugs by inducing MCL1 acting as an antiapoptotic factor. Cancer Res 58(23):5565-5569
36. Fragoso R, Pereira T, Wu Y, Zhu Z, Cabeçadas J, Dias S (2006) VEGFR-1 (FLT-1) activation modulates acute lymphoblastic leukemia localization and survival within the bone marrow, determining the onset of extramedullary disease. Blood 107(4):1608-1616. doi: 10.1182/blood-2005-06-2530
37. Hinz M, Krappmann D, Eichten A, Heder A, Scheidereit C, Strauss M (1999) NF-κB function in growth control: regulation of cyclin D1 expression and G0/G1-to-S-phase transition. Mol Cell Biol 19(4):2690-2698